Abstract Number: 040 • 2023 Pediatric Rheumatology Symposium
HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Over the last two decades, some children with systemic juvenile idiopathic arthritis (SJIA) have developed a severe form of interstitial lung disease (ILD) termed…Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…Abstract Number: L09 • 2019 ACR/ARP Annual Meeting
A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…Abstract Number: 200 • 2019 ACR/ARP Annual Meeting
A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records
Background/Purpose: Rapidly expanding collections of Electronic Medical Records (EMR) form a valuable resource for clinical research. Besides entries with a standardized format, EMRs often also…Abstract Number: 2956 • 2018 ACR/ARHP Annual Meeting
Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period
Background/Purpose: The opioid epidemic in the U.S. has led to similar concerns about prescribed opioids in the U.K. In new users, the rate of escalation…Abstract Number: 1012 • 2018 ACR/ARHP Annual Meeting
Inhibition of Inflammation and Oxidative Stress in Systemic Sclerosis (SSc) Macrophages
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown etiology that is characterized by vasculopathy, fibrosis, and inflammation. Our work and that of…Abstract Number: 1412 • 2018 ACR/ARHP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Current Therapies for the Treatment of Hyperimmunoglobulinemia D Syndrome and TNF Receptor-Associated Periodic Syndrome
Background/Purpose: Hyperimmunoglobulinemia D syndrome (HIDS), also known as mevalonate kinase deficiency (MKD), and TNF receptor-associated periodic syndrome (TRAPS) are rare auto-inflammatory diseases grouped as periodic…Abstract Number: 1495 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055) was a Phase 3b/4, 1-year, double-blind, triple-dummy, active comparator-controlled…Abstract Number: 1547 • 2018 ACR/ARHP Annual Meeting
Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry
Background/Purpose: Several previous reports suggest that obesity impairs the effectiveness and drug survival of anti-TNF-α agents in rheumatoid arthritis (RA). The aim of the study…Abstract Number: 1853 • 2018 ACR/ARHP Annual Meeting
Paternal Use of Methotrexate (MTX) and Congenital Malformations – a Systematic Review and Meta-Analysis
Background/Purpose: In rheumatology, fertile men and women are commonly treated with methotrexate (MTX). Maternal preconceptional MTX exposure is teratogenic, but less is known about paternal…Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…Abstract Number: 1931 • 2018 ACR/ARHP Annual Meeting
Abundance of Plasma Microbial Small RNAs Are Predictive of Improvement in Disease Activity after DMARD Initiation for Rheumatoid Arthritis
Background/Purpose: Small RNAs (sRNAs) are important regulators of biological processes and are potential biomarkers of disease and drug response. We previously found that microbial sRNAs…Abstract Number: 1412 • 2017 ACR/ARHP Annual Meeting
Yra-1909 suppresses Production of Pro-Inflammatory Mediators and MMPs through Downregulating Akt, p38, JNK and NF-κb Activation in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplastic synovial pannus tissue, which mediates destruction of cartilage and bone. Fibroblast-like synoviocyte (FLS) are a key component…Abstract Number: 1444 • 2017 ACR/ARHP Annual Meeting
Targeted Therapeutic Delivery to Cartilage with Knottin Proteins
Background/Purpose: Arthritic diseases affect more than 50 million Americans and, although there are many etiologies, the common manifestation of the disease is pain and limited…Abstract Number: 1945 • 2017 ACR/ARHP Annual Meeting
Repositioning Suramin As a Cartilage-Protective Drug
Background/Purpose: Drug repositioning is a recent pharmaceutical strategy to discover new uses for market-approved drugs with known safety profiles that can provide quick transition from…
ACR Meeting Abstracts